Drug profile

The FDA adverse-event record for Seresto Collar

38 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Seresto Collar. See the species affected, top reactions, and outcomes below.

38
adverse-event reports
5.3%
death-coded share
Dog
most-reported species
6
Lack of efficacy (ectoparasite) - tick NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
38
Total Reports
2
Deaths Reported
5.3%
Death Rate

Active Ingredients

Seresto Collar

Administration Routes

TopicalUnknown

Species Affected

Dog 33
Cat 5

Most Affected Breeds

Shepherd Dog - German 6
Retriever - Labrador 6
Domestic Shorthair 4
Retriever - Golden 4
Shepherd Dog - Australian 3
Spitz - German Pomeranian 2
Boxer (German Boxer) 2
Pit Bull 1
Cat (other) 1
Terrier - Yorkshire 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - tick NOS 6
Seizure NOS 5
Lack of efficacy (bacteria) - Borrelia 5
Lack of efficacy (ectoparasite) - flea 4
Lack of efficacy (bacteria) - Anaplasma 4
Vomiting 3
Lack of efficacy (bacteria) - Ehrlichia 3
Restlessness 2
Licking 2
Itching 2
Lack of efficacy (bacteria) - NOS 2
Fever 2

Outcome Breakdown

Ongoing
27 (71.1%)
Outcome Unknown
6 (15.8%)
Recovered/Normal
3 (7.9%)
Euthanized
2 (5.3%)

Seresto Collar Adverse Event Insights

38 reports name Seresto Collar; 2 recorded a death outcome (5.3% of reported events, not a population-level mortality rate). Active ingredient: Seresto Collar. Administration routes: Topical, Unknown.

By species: Dog (33 reports), Cat (5 reports). By breed: Shepherd Dog - German (6), Retriever - Labrador (6), Domestic Shorthair (4).

Leading clinical signs: Lack of efficacy (ectoparasite) - tick NOS (6), Seizure NOS (5), Lack of efficacy (bacteria) - Borrelia (5), Lack of efficacy (ectoparasite) - flea (4). Outcome, 38 coded reports: Ongoing leads at 71.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.